UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027155
Receipt number R000031120
Scientific Title The clinical study to examine efficacies of BSL5-170327C and BSL5-170327S on healthy skin
Date of disclosure of the study information 2017/05/15
Last modified on 2017/10/27 07:47:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The clinical study to examine efficacies of BSL5-170327C and BSL5-170327S on healthy skin

Acronym

The clinical study to examine efficacies of BSL5-170327C and BSL5-170327S on healthy skin

Scientific Title

The clinical study to examine efficacies of BSL5-170327C and BSL5-170327S on healthy skin

Scientific Title:Acronym

The clinical study to examine efficacies of BSL5-170327C and BSL5-170327S on healthy skin

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of the efficacy of BSL5-170327C and BSL5-170327S on healthy skin.
BSL5-170327C and BSL5-170327S are used as the code name of the materials.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Evaluation of the dermatological assessment, sebum composition, gene expressions, skin moisture content, and transepidermal water loss before and after the application of BSL5-170327C, as well as the continuous applications of both BSL5-170327C and BSL5-170327S.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Panelists will apply BSL5-170327C on their full face twice a day for 3 weeks, and then cleanse with launched product followed by placebo toner twice a day for 2 weeks.

Interventions/Control_2

Panelists will apply BSL5-170327C on their full face twice a day for 3 weeks, and then cleanse with launched product followed by BSL5-170327S twice a day for 2 weeks.

Interventions/Control_3

Panelists will apply launched product on their full face twice a day for 3 weeks, and then cleanse with launched product followed by placebo toner twice a day for 2 weeks.

Interventions/Control_4

Panelists will apply launched product on their full face twice a day for 3 weeks, and then cleanse with launched product followed by BSL5-170327S twice a day for 2 weeks.

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

49 years-old >=

Gender

Male

Key inclusion criteria

Panelists who are Japanese males ranging from 20-49 years old.

Key exclusion criteria

-Panelists with illnesses or diseases which in the opinion of the investigators, might interfere with the conduct of the study or the interpretation of results. Especially panelists with any skin irritation, skin condition (such as rosacea, eczema, atopic dermatitis, or psoriasis), or severe acne on their faces.
-Panelists who take any supplements, OTC or prescription medications, especially anti-inflammation agents, anti-bacterial agents, analgesic agents, hormonal agents, laxative agents, intestinal agents, etc.
-Panelists under the care of a doctor taking prescription medication (topical) for any facial skin issues.
-Panelists who have used any pore strips within 2 weeks of the first visit.
-Panelists who tend to have noticeable beard and whisker hair within 1 day after shaving.
-Panelists with allergy or sensitivity to any facial care product, facial moisturizer, facial cleanser, pore strip, or to any specific ingredient or fragrance used in these types of products.
-Panelists who cannot refrain from sun exposure, tanning beds, sunless tanners, pore strips, and skin lightening products until the study completes.
-Panelists who cannot refrain from facial cleansing and shaving on the days of evaluation visits.
-Panelists currently participating in, or scheduled to participate in, another facial study during the study period.
-Panelists having any conditions which in the opinion of the investigators, might interfere with the conduct of the study or the interpretation of results.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshito Takahashi

Organization

Kao Corporation

Division name

Biological Science Research

Zip code


Address

5-3-28, Kotobuki-machi, Odawara-shi, Kanagawa, 250-0002, JAPAN

TEL

0465-34-6116

Email

takahashi.yoshito@kao.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naoki Oya

Organization

Kao Corporation

Division name

Biological Science Research

Zip code


Address

2606, Akabane, Ichikai-machi, haga-gun, Tochigi, 321-3497, JAPAN

TEL

0285-68-7498

Homepage URL


Email

ooya.naoki@kao.co.jp


Sponsor or person

Institute

Kao Corporation

Institute

Department

Personal name



Funding Source

Organization

Kao Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

花王株式会社(東京都)


Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 03 Month 27 Day

Date of IRB


Anticipated trial start date

2017 Year 05 Month 19 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 04 Month 27 Day

Last modified on

2017 Year 10 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031120


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name